Zobrazeno 1 - 10
of 64
pro vyhledávání: '"John Yi"'
Publikováno v:
Regular and Young Investigator Award Abstracts.
Publikováno v:
Regular and Young Investigator Award Abstracts.
Publikováno v:
Day 1 Mon, May 02, 2022.
Measurement performance assurance for subsea multiphase flow meters (MPFM) can derive motivation from several sources of technical and/or business need, ranging from well surveillance to flow assurance monitoring, to production allocation among commi
Autor:
John Yi, Patrick Zimmerman, Jonathan Chow, Katrina Hawkins, Mark Munoz, David Yamane, Jordan Estroff
Publikováno v:
Critical Care Medicine. 51:397-397
Autor:
Alexandra Aquino-Acevedo, Hope Knochenhauer, Melanie Ortiz-León, Yadiel Rivera-López, Margarita Bonilla-Claudio, John Yi, Rebecca Previs, Guillermo Armaiz-Pena
Publikováno v:
Gynecologic Oncology. 166:S143
Autor:
Hope Knochenhauer, Shonagh Russell, Regina Whitaker, John Yi, Kyle Strickland, Rebecca Previs
Publikováno v:
Gynecologic Oncology. 166:S135
Publikováno v:
Heliyon, Vol 10, Iss 16, Pp e35717- (2024)
The increasing demand for sustainable energy solutions has driven interest in the utilization of agricultural residues, such as coconut shells, for bio-briquette production. This study investigates the impact of binder types (cassava and corn) and co
Externí odkaz:
https://doaj.org/article/37c7207c4c6e49a29ad25a74ec664231
Publikováno v:
Seminars in Orthodontics. 24:155-190
Tooth transpositions are relatively rare, and unless x-rays are obtained, they may go unnoticed until teeth begin to erupt. The prevalence, possible etiologies, and clinical considerations for different treatment options are reviewed in various class
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jessica A. Sorrentino, Janet K. Horton, Subing Cao, Aaron D. Stevens, John Yi, Antoinette R. Tan, Joyce O'Shaughnessy
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A365-A365
BackgroundTrilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor approved to reduce the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (myeloprotection). In a randomized, open-l